Eupraxia Pharmaceuticals IncTSX:EPRXView on NASDAQ
- LAST PRICE4.7700
- TODAY'S CHANGE (%)-0.2600 (-5.1690%)
- Bid / Lots4.7000/ 10
- Ask / Lots4.8000/ 3
- Open / Previous Close4.8500 / 5.0300
- Day Range
- 52 Week Range
- Volume44,038
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EPRX |
|---|---|---|
| 09:32 ET | 23100 | 5.03 |
| 09:35 ET | 500 | 4.94 |
| 09:42 ET | 700 | 4.97 |
| 09:57 ET | 1400 | 5.03 |
| 10:00 ET | 4300 | 4.98 |
| 10:02 ET | 300 | 4.95 |
| 10:08 ET | 2000 | 4.96 |
| 10:26 ET | 100 | 4.86 |
| 10:31 ET | 1200 | 4.85 |
| 10:47 ET | 100 | 4.7 |
| 10:49 ET | 1300 | 4.68 |
| 10:51 ET | 1200 | 4.57 |
| 11:00 ET | 300 | 4.7 |
| 11:16 ET | 100 | 4.71 |
| 11:18 ET | 1500 | 4.7 |
| 11:20 ET | 500 | 4.7 |
| 11:34 ET | 700 | 4.7 |
| 11:41 ET | 100 | 4.7 |
| 12:32 ET | 400 | 4.75 |
| 01:31 ET | 100 | 4.73 |
| 01:49 ET | 2100 | 4.7 |
| 02:12 ET | 100 | 4.75 |
| 02:41 ET | 400 | 4.74 |
| 03:32 ET | 700 | 4.73 |
| 03:44 ET | 200 | 4.76 |
| 03:46 ET | 500 | 4.77 |
| 04:00 ET | 200 | 4.77 |
Yesterday
DJ Eupraxia Pharma Shares Jump Following Data From Eosinophilic Esophagitis Trial, from 10:36AM ET on Wednesday Nov 20, 2024 by Dow Jones
10:36AM ET on Wednesday Nov 20, 2024 by Dow JonesEupraxia's DiffuSphere(TM) Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months, from 7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 14, 2024
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting, from 5:00PM ET on Thursday Nov 14, 2024 by Dow Jones
5:00PM ET on Thursday Nov 14, 2024 by Dow JonesDJ Eupraxia Pharmaceuticals Initiated at Buy by Rodman & Renshaw, from 7:12AM ET on Thursday Nov 14, 2024 by Dow Jones
7:12AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Eupraxia Pharmaceuticals Inc | 179.2M | -3.5x | --- |
Cybin Inc | 311.3M | -1.6x | --- |
Zentek Ltd | 178.0M | -15.1x | --- |
Bright Minds Biosciences Inc | 326.5M | -49.1x | --- |
Cardiol Therapeutics Inc | 174.2M | -4.2x | --- |
NervGen Pharma Corp | 157.5M | -6.8x | --- |
Company Information
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.
Contact Information
- Headquarters
- 201-2067 Cadboro Bay Rd.VICTORIA, BC, Canada V8R 5G4
- Phone
- 250-590-3968
- Fax
- 250-590-2588
Executives
- Independent Chairman of the Board
- Simon Pimstone
- President, Chief Financial Officer
- Bruce Cousins
- Chief Executive Officer, Director
- James Helliwell
- Chief Operating and Scientific Officer
- Amanda Malone
- Chief Business Officer
- Paul Brennan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $179.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-1.38 |
Book Value | $0.11 |
P/E Ratio | -3.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
